Topic

Articles

Through the acquisition, Thermo Fisher will have access to Mesa’s PCR-based rapid point-of-care testing platform for detecting infectious diseases.

Thermo Fisher to Acquire Mesa Biotech for $450 Million

The companies will develop up to three CD3-engaging T-cell redirecting bispecific antibody therapies using Merus' proprietary Biclonics platform.

Loxo Oncology at Lilly and Merus Enter into Bispecific Antibody Partnership for up to $1.6 Billion

Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment.

Thermo Fisher Completes $875-Million Acquisition of Novasep’s Viral Vector Manufacturing Business

This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.

US Government to Purchase Additional Doses of Regeneron’s COVID-19 Antibody Cocktail

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.

Precision Medicine Group Acquires Project Farma

The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines as well as multinationals with manufacturing requirements in China.

Cytiva Delivers Chinese Biomanufacturing Facility to Lonza

The acquisition will give Sanofi full global rights to KY1005, Kymab’s fully human monoclonal antibody that binds to OX40-Ligand, giving it the potential to treat a variety of immune-mediated diseases and inflammatory disorders. 

Sanofi to Acquire Kymab for $1.4 Billion

Under the terms of the agreement, operations will be initiated at Lonza’s Houston, TX Center of Excellence where Lonza will handle process development activities for late-clinical and commercial-scale GMP manufacturing of the cell therapy.

Lonza to Partner with Capricor Therapeutics for the Development of Duchenne Muscular Dystrophy Cell Therapy 

Baxter will provide commercial-scale manufacturing services at its Halle/Westfalen, Germany facility to prepare Novavax’s COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.

Deals, Development and Manufacturing